Cytosolic phospholipase A2 activation correlates with HER2 overexpression and mediates estrogen-dependent breast cancer cell growth

Molecular Endocrinology

Volumn 24, Issue 5, 2010, Pages 953-968

  Caiazza, Francesco ^a   Harvey, Brian J ^a   Thomas, Warren ^a  

^a BEAUMONT HOSPITAL   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOSOLIC PHOSPHOLIPASE A2; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTRADIOL; MATRIX METALLOPROTEINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; SMALL INTERFERING RNA; ESTROGEN; HER2 PROTEIN, HUMAN; PHOSPHOLIPASE A2 GROUP IV;

ARTICLE; BREAST CANCER; CANCER GROWTH; CONTROLLED STUDY; CORRELATION ANALYSIS; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; BREAST TUMOR; CELL PROLIFERATION; DRUG EFFECT; GENE EXPRESSION REGULATION; GENETICS; IMMUNOPRECIPITATION; METABOLISM; PHOSPHORYLATION; PROTEIN BINDING; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA INTERFERENCE; TUMOR CELL LINE; WESTERN BLOTTING;

BLOTTING, WESTERN; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; ESTRADIOL; ESTROGENS; GENE EXPRESSION REGULATION, NEOPLASTIC; GROUP IV PHOSPHOLIPASES A2; HUMANS; IMMUNOPRECIPITATION; PHOSPHORYLATION; PROTEIN BINDING; RECEPTOR, ERBB-2; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA INTERFERENCE; SIGNAL TRANSDUCTION;

EID: 77954853265     PISSN: 08888809     EISSN: None     Source Type: Journal    
DOI: 10.1210/me.2009-0293     Document Type: Article

References (71)

1. Park JY, Pillinger MH, Abramson SB 2006 Prostaglandin E2 synthesis and secretion: the role of PGE2 synthases. Clin Immunol 119:229-240
2. Leslie CC 1997 Properties and regulation of cytosolic phospholipase A2. J Biol Chem 272:16709-16712
3. Heasley LE, Thaler S, Nicks M, Price B, Skorecki K, Nemenoff RA 1997 Induction of cytosolic phospholipase A2 by oncogenic Ras in human non-small cell lung cancer. J Biol Chem 272:14501-14504
4. Panel V, Boëlle PY, Ayala-Sanmartin J, Jouniaux AM, Hamelin R, Masliah J, Trugnan G, Fléjou JF, Wendum D 2006 Cytoplasmic phospholipase A2 expression in human colon adenocarcinoma is correlated with cyclooxygenase-2 expression and contributes to prostaglandin E2 production. Cancer Lett 243:255-263
5. Patel MI, Singh J, Niknami M, Kurek C, Yao M, Lu S, Maclean F, King NJ, Gelb MH, Scott KF, Russell PJ, Boulas J, Dong Q 2008 Cytosolic phospholipase A2-α: a potential therapeutic target for prostate cancer. Clin Cancer Res 14:8070-8079
6. Nakanishi M, Rosenberg DW 2006 Roles of cPLA2α and arachidonic acid in cancer. Biochim Biophys Acta 1761:1335-1343 (Pubitemid 44738711)
7. Ristimäki A, Sivula A, Lundin J, Lundin M, Salminen T, Haglund C, Joensuu H, Isola J 2002 Prognostic significance of elevated cyclooxygenase-2 expression in breast cancer. Cancer Res 62: 632-635
8. Basu GD, Pathangey LB, Tinder TL, Lagioia M, Gendler SJ, Mukherjee P 2004 Cyclooxygenase-2 inhibitor induces apoptosis in breast cancer cells in an in vivo model of spontaneous metastatic breast cancer. Mol Cancer Res 2:632-642 (Pubitemid 39557666)
9. Harris RE, Beebe-Donk J, Alshafie GA 2007 Cancer chemoprevention by cyclooxygenase 2 (COX-2) blockade: results of case control studies. Subcell Biochem 42:193-212
10. Khuder SA, Mutgi AB 2001 Breast cancer and NSAID use: a meta-analysis. Br J Cancer 84:1188-1192
11. Thomas W, Caiazza F, Harvey BJ 2008 Estrogen, phospholipase A and breast cancer. Front Biosci 13:2604-2613
12. Wang SC, Lien HC, Xia W, Chen IF, Lo HW, Wang Z, Ali-Seyed M, Lee DF, Bartholomeusz G, Ou-Yang F, Giri DK, Hung MC 2004 Binding at and transactivation of the COX-2 promoter by nuclear tyrosine kinase receptor ErbB-2. Cancer Cell 6:251-261
13. Zhao Y, Agarwal VR, Mendelson CR, Simpson ER 1996 Estrogen biosynthesis proximal to a breast tumor is stimulated by PGE2 via cyclic AMP, leading to activation of promoter II of the CYP19 (aromatase) gene. Endocrinology 137:5739-5742
14. Henderson BE, Feigelson HS 2000 Hormonal carcinogenesis. Carcinogenesis 21:427-433
15. Russo J, Russo IH 2006 The role of estrogen in the initiation of breast cancer. J Steroid Biochem Mol Biol 102:89-96 (Pubitemid 44750629)
16. Ascenzi P, Bocedi A, Marino M 2006 Structure-function relationship of estrogen receptor α and β: impact on human health. Mol Aspects Med 27:299-402
17. Jordan VC, Brodie AM 2007 Development and evolution of therapies targeted to the estrogen receptor for the treatment and prevention of breast cancer. Steroids 72:7-25
18. Howell A 2006 Pure oestrogen antagonists for the treatment of advanced breast cancer. Endocr Relat Cancer 13:689-706
19. Katzenellenbogen BS, Katzenellenbogen JA 2000 Estrogen receptor transcription and transactivation: estrogen receptor α and estrogen receptor β: regulation by selective estrogen receptor modulators and importance in breast cancer. Breast Cancer Res 2:335-344
20. Migliaccio A, Di Domenico M, Castoria G, de Falco A, Bontempo P, Nola E, Auricchio F 1996 Tyrosine kinase/p21ras/MAP-kinase pathway activation by estradiol-receptor complex in MCF-7 cells. EMBO J 15:1292-1300
21. Filardo EJ, Thomas P 2005 GPR30: a seven-transmembrane-spanning estrogen receptor that triggers EGF release. Trends Endocrinol Metab 16:362-367
22. Razandi M, Pedram A, Greene GL, Levin ER 1999 Cell membrane and nuclear estrogen receptors (ERs) originate from a single transcript: studies of ERα and ERβ expressed in Chinese hamster ovary cells. Mol Endocrinol 13:307-319
23. Razandi M, Pedram A, Park ST, Levin ER 2003 Proximal events in signaling by plasma membrane estrogen receptors. J Biol Chem 278:2701-2712 (Pubitemid 36801351)
24. Levin ER 2003 Bidirectional signaling between the estrogen receptor and the epidermal growth factor receptor. Mol Endocrinol 17: 309-317
25. Pietras RJ 2003 Interactions between estrogen and growth factor receptors in human breast cancers and the tumor-associated vasculature. Breast J 9:361-373
26. Howe LR 2007 Inflammation and breast cancer. Cyclooxygenase/ prostaglandin signaling and breast cancer. Breast Cancer Res 9:210
27. Nakatsugi S, Ohta T, Kawamori T, Mutoh M, Tanigawa T, Watanabe K, Sugie S, Sugimura T, Wakabayashi K 2000 Chemoprevention by nimesulide, a selective cyclooxygenase-2 inhibitor, of 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP)-induced mammary gland carcinogenesis in rats. Jpn J Cancer Res 91:886-892
28. Harris RE, Alshafie GA, Abou-Issa H, Seibert K 2000 Chemoprevention of breast cancer in rats by celecoxib, a cyclooxygenase 2 inhibitor. Cancer Res 60:2101-2103
29. Lanza-Jacoby S, Miller S, Flynn J, Gallatig K, Daskalakis C, Masferrer JL, Zweifel BS, Sembhi H, Russo IH 2003 The cyclooxygenase-2 inhibitor, celecoxib, prevents the development of mammary tumors in Her-2/neu mice. Cancer Epidemiol Biomarkers Prev 12:1486-1491
30. Howe LR, Chang SH, Tolle KC, Dillon R, Young LJ, Cardiff RD, Newman RA, Yang P, Thaler HT, Muller WJ, Hudis C, Brown AM, Hla T, Subbaramaiah K, Dannenberg AJ 2005 HER2/neuinduced mammary tumorigenesis and angiogenesis are reduced in cyclooxygenase-2 knockout mice. Cancer Res 65:10113-10119
31. Chang SH, Liu CH, Conway R, Han DK, Nithipatikom K, Trifan OC, Lane TF, Hla T 2004 Role of prostaglandin E2-dependent angiogenic switch in cyclooxygenase 2-induced breast cancer progression. Proc Natl Acad Sci USA 101:591-596
32. Liu CH, Chang SH, Narko K, Trifan OC, Wu MT, Smith E, Haudenschild C, Lane TF, Hla T 2001 Overexpression of cyclooxygenase-2 is sufficient to induce tumorigenesis in transgenic mice. J Biol Chem 276:18563-18569
33. Rolland PH, Martin PM, Jacquemier J, Rolland AM, Toga M 1980 Prostaglandin in human breast cancer: evidence suggesting that an elevated prostaglandin production is a marker of high metastatic potential for neoplastic cells. J Natl Cancer Inst 64:1061-1070
34. Bandyopadhyay GK, Imagawa W, Wallace D, Nandi S 1987 Linoleate metabolites enhance the in vitro proliferative response of mouse mammary epithelial cells to epidermal growth factor. J Biol Chem 262:2750-2756
35. Ma X, Kundu N, Rifat S, Walser T, Fulton AM 2006 Prostaglandin E receptor EP4 antagonism inhibits breast cancer metastasis. Cancer Res 66:2923-2927
36. Mauritz I, Westermayer S, Marian B, Erlach N, Grusch M, Holzmann K 2006 Prostaglandin E2 stimulates progression-related gene expression in early colorectal adenoma cells. Br J Cancer 94:1718-1725
37. Harvey BJ, Alzamora R, Healy V, Renard C, Doolan CM 2002 Rapid responses to steroid hormones: from frog skin to human colon. A homage to Hans Ussing. Biochim Biophys Acta 1566: 116-128
38. Fiorini S, Ferretti ME, Biondi C, Pavan B, Lunghi L, Paganetto G, Abelli L 2003 17β-Estradiol stimulates arachidonate release from human amnion-like WISH cells through a rapid mechanism involving a membrane receptor. Endocrinology 144:3359-3367
39. Thomas W, Coen N, Faherty S, Flatharta CO, Harvey BJ 2006 Estrogen induces phospholipase A2 activation through ERK1/2 to mobilize intracellular calcium in MCF-7 cells. Steroids 71:256-265
40. Marino M, Caiazza F 2007 Estrogen signal transduction pathways from plasma membrane to the nucleus. In: Grachevsky NO, ed. Signal transduction research trends. New York: Nova Science Publishers; 17-44
41. Song RX, Zhang Z, Chen Y, Bao Y, Santen RJ 2007 Estrogen signaling via a linear pathway involving insulin-like growth factor I receptor, matrix metalloproteinases, and epidermal growth factor receptor to activate mitogen-activated protein kinase in MCF-7 breast cancer cells. Endocrinology 148:4091-4101
42. Filardo EJ, Quinn JA, Bland KI, Frackelton Jr AR 2000 Estrogen-induced activation of Erk-1 and Erk-2 requires the G protein-coupled receptor homolog, GPR30, and occurs via trans-activation of the epidermal growth factor receptor through release of HB-EGF. Mol Endocrinol 14:1649-1660
43. Mitamura T, Higashiyama S, Taniguchi N, Klagsbrun M, Mekada E 1995 Diphtheria toxin binds to the epidermal growth factor (EGF)-like domain of human heparin-binding EGF-like growth factor/ diphtheria toxin receptor and inhibits specifically its mitogenic activity. J Biol Chem 270:1015-1019
44. Song RX, Chen Y, Zhang Z, Bao Y, Yue W, Wang JP, Fan P, Santen RJ 6 October 2009 Estrogen utilization of IGF-1-R and EGF-R to signal in breast cancer cells. J Steroid Biochem Mol Biol 10.1016/ j.jsbmb.2009.09.018
45. Landgraf R 2007 HER2 therapy. HER2 (ERBB2): functional diversity from structurally conserved building blocks. Breast Cancer Res 9:202
46. Moasser MM 2007 The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesis. Oncogene 26:6469-6487
47. Kao J, Salari K, Bocanegra M, Choi YL, Girard L, Gandhi J, Kwei KA, Hernandez-Boussard T, Wang P, Gazdar AF, Minna JD, Pollack JR 2009 Molecular profiling of breast cancer cell lines defines relevant tumor models and provides a resource for cancer gene discovery. PLoS One 4:e6146
48. Nahta R, Esteva FJ 2006 Herceptin: mechanisms of action and resistance. Cancer Lett 232:123-138
49. Osipo C, Patel P, Rizzo P, Clementz AG, Hao L, Golde TE, Miele L 2008 ErbB-2 inhibition activates Notch-1 and sensitizes breast cancer cells to a γ-secretase inhibitor. Oncogene 27:5019-5032
50. Flouriot G, Brand H, Denger S, Metivier R, Kos M, Reid G, Sonntag-Buck V, Gannon F 2000 Identification of a new isoform of the human estrogen receptor-α (hER-α) that is encoded by distinct transcripts and that is able to repress hER-α activation function 1. EMBO J 19:4688-4700
51. Wang Z, Zhang X, Shen P, Loggie BW, Chang Y, Deuel TF 2005 Identification, cloning, and expression of human estrogen receptor-α36, a novel variant of human estrogen receptor-α66. Biochem Biophys Res Commun 336:1023-1027
52. Li L, Haynes MP, Bender JR 2003 Plasma membrane localization and function of the estrogen receptor α variant (ER46) in human endothelial cells. Proc Natl Acad Sci USA 100:4807-4812 (Pubitemid 36457810)
53. Penot G, Le Péron C, Mérot Y, Grimaud-Fanouillère E, Ferrière F, Boujrad N, Kah O, Saligaut C, Ducouret B, Métivier R, Flouriot G 2005 The human estrogen receptor-α isoform hERα46 antagonizes the proliferative influence of hERα66 in MCF7 breast cancer cells. Endocrinology 146:5474-5484
54. Wang Z, Zhang X, Shen P, Loggie BW, Chang Y, Deuel TF 2006 A variant of estrogen receptor-α, hER-α36: transduction of estrogen-and antiestrogen-dependent membrane-initiated mitogenic signaling. Proc Natl Acad Sci USA 103:9063-9068
55. Zheng A, Kallio A, Härkönen P 2007 Tamoxifen-induced rapid death of MCF-7 breast cancer cells is mediated via extracellularly signal-regulated kinase signaling and can be abrogated by estrogen. Endocrinology 148:2764-2777
56. Cuendet M, Pezzuto JM 2000 The role of cyclooxygenase and lipoxygenase in cancer chemoprevention. Drug Metabol Drug Interact 17:109-157 (Pubitemid 32049022)
57. Aoki J 2004 Mechanisms of lysophosphatidic acid production. Semin Cell Dev Biol 15:477-489
58. Abir F, Alva S, Kaminski DL, Longo WE 2005 The role of arachidonic acid regulatory enzymes in colorectal disease. Dis Colon Rectum 48:1471-1483
59. Hassan S, Carraway RE 2006 Involvement of arachidonic acid metabolism and EGF receptor in neurotensin-induced prostate cancer PC3 cell growth. Regul Pept 133:105-114
60. Lanza-Jacoby S, Burd R, Rosato Jr FE, McGuire K, Little J, Nougbilly N, Miller S 2006 Effect of simultaneous inhibition of epidermal growth factor receptor and cyclooxygenase-2 in HER-2/ neu-positive breast cancer. Clin Cancer Res 12:6161-6169
61. Levin ER, Pietras RJ 2008 Estrogen receptors outside the nucleus in breast cancer. Breast Cancer Res Treat 108:351-361
62. Pietras RJ, Arboleda J, Reese DM, Wongvipat N, Pegram MD, Ramos L, Gorman CM, Parker MG, Sliwkowski MX, Slamon DJ 1995 HER-2 tyrosine kinase pathway targets estrogen receptor and promotes hormone-independent growth in human breast cancer cells. Oncogene 10:2435-2446
63. Mariggiò S, Filippi BM, Iurisci C, Dragani LK, De Falco V, Santoro M, Corda D 2007 Cytosolic phospholipase A2α regulates cell growth in RET/PTC-transformed thyroid cells. Cancer Res 67: 11769-11778
64. Mariggiò S, Sebastià J, Filippi BM, Iurisci C, Volonté C, Amadio S, De Falco V, Santoro M, Corda D 2006 A novel pathway of cell growth regulation mediated by a PLA2alpha-derived phosphoinositide metabolite. FASEB J 20:2567-2569
65. Herbert SP, Ponnambalam S, Walker JH 2005 Cytosolic phospholipase A2-α mediates endothelial cell proliferation and is inactivated by association with the Golgi apparatus. Mol Biol Cell 16: 3800-3809
66. Markaverich BM, Crowley J, Rodriquez M, Shoulars K, Thompson T 2007 Tetrahydrofurandiol stimulation of phospholipase A2, lipoxygenase, and cyclooxygenase gene expression and MCF-7 human breast cancer cell proliferation. Environ Health Perspect 115: 1727-1731
67. Seno K, Okuno T, Nishi K, Murakami Y, Watanabe F, Matsuura T, Wada M, Fujii Y, Yamada M, Ogawa T, Okada T, Hashizume H, Kii M, Hara S, Hagishita S, Nakamoto S, Yamada K, Chikazawa Y, Ueno M, Teshirogi I, Ono T, Ohtani M 2000 Pyrrolidine inhibitors of human cytosolic phospholipase A2. J Med Chem 43:1041-1044
68. Smith PK, Krohn RI, Hermanson GT, Mallia AK, Gartner FH, Provenzano MD, Fujimoto EK, Goeke NM, Olson BJ, Klenk DC 1985 Measurement of protein using bicinchoninic acid. Anal Biochem 150:76-85
69. Peghini PL, Iwamoto M, Raffeld M, Chen YJ, Goebel SU, Serrano J, Jensen RT 2002 Overexpression of epidermal growth factor and hepatocyte growth factor receptors in a proportion of gastrinomas correlates with aggressive growth and lower curability. Clin Cancer Res 8:2273-2285 (Pubitemid 34753601)
70. Ramakers C, Ruijter JM, Deprez RH, Moorman AF 2003 Assumption-free analysis of quantitative real-time polymerase chain reaction (PCR) data. Neurosci Lett 339:62-66
71. Maggiolini M, Vivacqua A, Fasanella G, Recchia AG, Sisci D, Pezzi V, Montanaro D, Musti AM, Picard D, Andò S 2004 The G protein-coupled receptor GPR30 mediates c-fos up-regulation by 17β-estradiol and phytoestrogens in breast cancer cells. J Biol Chem 279: 27008-27016